Seoul, Korea - Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities will present a technical session on Global Trial Solutions for Biotechs at BIOPLUS-INTERPHEX KOREA 2023 for biotechs planning regional or global trials.
Novotech’s Vice President, Global Head of Clinical Services Yooni Kim will open the session which will be followed by presentations from senior Novotech experts.
• “Pre-Clinical requirements for successful clinical trial entry” – presented by Dr. Babaji Yadav, Associate Director and Principal Toxicologist, Novotech Drug Development Consulting
• “Successful global clinical trial solutions for biotechs” – presented by HyunKyoung Kim, Project Director, Novotech
Then a panel discussion will follow lead by Yooni Kim and featuring biotech leaders and Novotech sector specialists.
Technical Session by Novotech
Time: 3:10pm (Korea)
Date: 12 July, 2023
Book a meeting with the Novotech team here or attend the Technical Session.
The conference which is co-hosted by Korea Biotechnology Industry Organization and Reed Exhibition Korea (RX Korea), and supported The Ministry of Trade, Industry and Energy is expected to attract more than 10,000 participants, 250 pharmaceutical and biotech companies, 400 exhibitors and features more than 20 conference sessions.
Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Novotech has been awarded a range of significant industry awards including a CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2022 award, and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed more than 45 Leading Site Partnership agreements over the last 3 years.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
For more information or to speak to an expert team member visit www.Novotech-CRO.com